BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 28276821)

  • 1. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N; Tsochatzis E
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.
    Djordjevic DB; Zdravkovic M; Nagorni A; Manolis A; Tsioufis C; Lovic D
    Curr Vasc Pharmacol; 2018; 16(3):228-238. PubMed ID: 28676026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
    Mathews SE; Kumar RB; Shukla AP
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
    Tai FW; Syn WK; Alazawi W
    Diabet Med; 2015 Sep; 32(9):1121-33. PubMed ID: 25683343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A; Wong RJ; Harrison SA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of non-alcoholic fatty liver disease.
    Jennison E; Patel J; Scorletti E; Byrne CD
    Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.